Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein
GlobeNewswireApr 25 07:00 ET
Express News | Kymera Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating and Target Price $53
Moomoo 24/7Apr 22 08:22 ET
Kymera Therapeutics Initiated at Outperform by Oppenheimer
Kymera Therapeutics Initiated at Outperform by Oppenheimer
Dow JonesApr 22 07:38 ET
Express News | Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53
Moomoo 24/7Apr 22 07:28 ET
Kymera Therapeutics Reveals Preclinical Data on Cancer-Fighting Drug KT-333 at AACR Meeting
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new
BenzingaApr 8 07:05 ET
Kymera Therapeutics(KYMR.US) Director Sells US$5.13 Million in Common Stocks
$Kymera Therapeutics(KYMR.US)$ Director Booth Bruce sold 127.54K shares of Common Stocks on Mar 14, 15, 2024 at an average price of $40.25 for a total value of $5.13 million.Source: Announcement What
moomoo NewsMar 15 20:05 ET
Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing
Bruce Booth, Director, on March 11, 2024, sold 353,357 shares in Kymera Therapeutics (KYMR) for $14,912,376. Following the Form 4 filing with the SEC, Booth has control over a total of 828,830 shares
MT NewswiresMar 14 10:26 ET
Kymera Therapeutics(KYMR.US) Director Sells US$14.91 Million in Common Stocks
$Kymera Therapeutics(KYMR.US)$ Director Booth Bruce sold 353.36K shares of Common Stocks on Mar 11, 12, 13, 2024 at an average price of $42.2 for a total value of $14.91 million. This transaction invo
moomoo NewsMar 13 20:33 ET
Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR)
Yahoo FinanceMar 4 23:27 ET
Express News | Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $54
Moomoo 24/7Mar 1 08:33 ET
Kymera Therapeutics (KYMR) Receives a Buy From Truist Financial
TipRanksMar 1 07:35 ET
Kymera Therapeutics(KYMR.US) Officer Sells US$18,000 in Common Stocks
$Kymera Therapeutics(KYMR.US)$ Officer Gollob Jared sold 400 shares of Common Stocks on Feb 27, 2024 at an average price of $45 for a total value of $18,000.Source: Announcement What is statement of c
moomoo NewsFeb 29 23:10 ET
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein
GlobeNewswireFeb 28 07:00 ET
Kymera Therapeutics Price Target Raised to $56.00/Share From $39.00 by Piper Sandler
Kymera Therapeutics Price Target Raised to $56.00/Share From $39.00 by Piper Sandler
Dow JonesFeb 27 10:38 ET
Express News | Piper Sandler Maintains Overweight on Kymera Therapeutics, Raises Price Target to $56
Moomoo 24/7Feb 27 10:27 ET
Maintaining Hold on Kymera Therapeutics Amidst Promising Pipeline and Industry Challenges
TipRanksFeb 25 23:27 ET
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, Kymera Therapeutics, Inc. (NASDAQ:KYMR) just kicked off its latest annual results with some very strong numbers. The overall earnings picture was okay, with revenues of US$79m
Simply Wall StFeb 25 08:45 ET
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their Forecasts
Yahoo FinanceFeb 24 09:54 ET
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
In the latest quarter, 4 analysts provided ratings for Kymera Therapeutics (NASDAQ:KYMR), showcasing a mix of bullish and bearish perspectives.The following table summarizes their recent ratings, shed
BenzingaFeb 23 15:00 ET
Earnings Call: Kymera Therapeutics Outlines Robust Pipeline and Financial Health
InvestingFeb 23 12:38 ET
No Data
No Data